Promising combo for tough leukemia stalls: trial ends early
NCT ID NCT05464836
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested two drugs, CB-103 and venetoclax, in adolescents and young adults with T-cell acute lymphoblastic leukemia (T-ALL) that had come back or not responded to treatment. The goal was to see if the combination could control the disease. However, the study was terminated early after enrolling only 2 participants, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CB-103 and venetoclax
- What this could lead to
- If this combination works, it could offer a new treatment option for young patients with hard-to-treat T-cell leukemia.
- What could go wrong
- The trial was terminated early with only 2 participants, so we have very little data. It is unclear if the combination is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's DNA guide better cancer care for kids?
- A guided path back to work after blood cancer: a trial tests the impact
- Can a new tracer light up cancer growth?
- Can a different immune drug cut viral infections after stem cell transplants?
- Can simple seated exercises boost strength and Well-Being during leukemia treatment?
- Can a Child's own words improve cancer care?